Clinicopathological significance and prognostic implications of Ube2v1 expression in colorectal cancer

Qiang Ma; Jin Bao; Naiying Sun; Xingjie Yang; Li Liu; Ying Chen; Wenjun Guo; Lixiang Gao

doi:10.3892/mi.2023.119

Clinicopathological significance and prognostic implications of Ube2v1 expression in colorectal cancer

Med Int (Lond). 2023 Oct 31;3(6):59. doi: 10.3892/mi.2023.119. eCollection 2023 Nov-Dec.

Authors

Qiang Ma¹, Jin Bao², Naiying Sun¹, Xingjie Yang¹, Li Liu¹, Ying Chen¹, Wenjun Guo¹, Lixiang Gao¹

Affiliations

¹ Department of Pathology, Sunshine Union Hospital, Weifang, Shandong 261000, P.R. China.
² Department of Pathology, Fangzi District People's Hospital, Weifang, Shandong 261200, P.R. China.

Abstract

The present study aimed to investigate the expression of ubiquitin-conjugating enzyme E2 variant 1 (Ube2v1) in colorectal cancer (CRC) and its clinical significance. The differential expression of Ube2v1 in CRC tissues and normal intestinal tissues, as well as the association between Ube2v1 expression and the prognosis of patients with CRC were analyzed using bioinformatics analyses. TIMER database analysis revealed higher Ube2v1 expression in CRC tissues than in normal intestinal tissues. Cancerous and normal tissues collected retrospectively from 37 cases of CRC between July, 2022 and June, 2023 were analyzed for Ube2v1 expression using immunohistochemistry, and the associations between Ube2v1 expression and the clinical pathological features of patients with CRC were analyzed. Ube2v1 expression was associated with lymph node metastasis in patients with CRC (P<0.05). However, bioinformatics analysis using the GEPIA2 and HPA database revealed that Ube2v1 was not associated with the overall survival of patients with CRC. On the whole, the present study demonstrates that due to its high expression and association with lymph node metastasis, Ube2v1 may serve as a potential target for the treatment of CRC.

Keywords: clinicopathology; colorectal cancer; immunohistochemistry; ubiquitin-conjugating enzyme E2 variant 1.

Grants and funding

Funding: The present study was supported by the Research Projects of Weifang Municipal Health Committee (grant no. WFWSJK-2022-239) and the Sunshine Union Hospital Research Project (grant no. 2022YGRH043).